Traders bought shares of Celgene Corp. (NASDAQ:CELG) on weakness during trading on Tuesday. $101.52 million flowed into the stock on the tick-up and $68.35 million flowed out of the stock on the tick-down, for a money net flow of $33.17 million into the stock. Of all equities tracked, Celgene Corp. had the 10th highest net in-flow for the day. Celgene Corp. traded down ($0.93) for the day and closed at $107.02

Several research firms have recently weighed in on CELG. BTIG Research reissued a “buy” rating and set a $140.00 price target on shares of Celgene Corp. in a report on Tuesday, May 24th. Jefferies Group reissued a “buy” rating and set a $140.00 price target on shares of Celgene Corp. in a report on Thursday, May 19th. Argus reissued a “buy” rating and set a $155.00 price target on shares of Celgene Corp. in a report on Wednesday, May 18th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corp. in a report on Wednesday, June 8th. Finally, Bank of America Corp. reissued a “buy” rating and set a $125.00 price target on shares of Celgene Corp. in a report on Wednesday, June 8th. Four analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the company. Celgene Corp. currently has a consensus rating of “Buy” and an average price target of $137.98.

The stock’s 50-day moving average is $109.94 and its 200 day moving average is $104.68. The firm has a market cap of $82.95 billion and a P/E ratio of 45.23.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.05. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same period in the prior year, the company posted $1.23 EPS. The firm’s revenue was up 20.9% on a year-over-year basis. On average, equities research analysts predict that Celgene Corp. will post $5.70 EPS for the current year.

In related news, Director James J. Loughlin sold 27,500 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $114.10, for a total transaction of $3,137,750.00. Following the completion of the sale, the director now owns 42,919 shares of the company’s stock, valued at approximately $4,897,057.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Robert J. Hugin sold 75,000 shares of the company’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the sale, the insider now directly owns 1,122,201 shares of the company’s stock, valued at approximately $112,399,652.16. The disclosure for this sale can be found here.

Several hedge funds have recently bought and sold shares of CELG. Nicholas Co. Inc. WI boosted its stake in Celgene Corp. by 3.1% in the fourth quarter. Nicholas Co. Inc. WI now owns 748,020 shares of the biopharmaceutical company’s stock valued at $89,582,000 after buying an additional 22,770 shares during the period. US Bancorp DE boosted its stake in Celgene Corp. by 4.9% in the fourth quarter. US Bancorp DE now owns 520,006 shares of the biopharmaceutical company’s stock valued at $62,276,000 after buying an additional 24,384 shares during the period. American International Group Inc. boosted its stake in Celgene Corp. by 1.1% in the fourth quarter. American International Group Inc. now owns 377,122 shares of the biopharmaceutical company’s stock valued at $45,164,000 after buying an additional 4,136 shares during the period. Birch Hill Investment Advisors LLC boosted its stake in Celgene Corp. by 2.4% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 301,312 shares of the biopharmaceutical company’s stock valued at $36,085,000 after buying an additional 7,160 shares during the period. Finally, KBC Group NV boosted its stake in Celgene Corp. by 8.3% in the fourth quarter. KBC Group NV now owns 277,271 shares of the biopharmaceutical company’s stock valued at $33,207,000 after buying an additional 21,335 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.